Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y educación

Enviado por remote_content el Lun, 28/10/2024 - 07:54

Enfermedades infecciosas

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Medicina Interna

Herramientas para identificar consumo y desperdicio de la dieta hospitalaria. Revisión Sistemática. Rev. chil. nutr.vol.49 no.2 Santiago

Abril 1, 2022

Neurología

"Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors. Mult Scler. 2022 Dec"

Diciembre 1, 2022

Medicina Crítica

Multinational prospective cohort study over 24 years of the risk factors for ventilator-associated pneumonia in 187 ICUs in 12 Latin American countries

Diciembre 29, 2022

28 Octubre, 2024